Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — OIS ASRS 2021

13 slides from Aerie Pharmaceuticals's conference presentation, Oct 7, 2021

  1. Slide 1: PRINT Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease

    Exhibit 99.1 PRINT® Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease Casey Kopczynski, PhD Chief Scientific Officer @ OIS ASRS 2021Exhibit 99.1 PRINT® Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease Casey Kopczynski, PhD Chief Scientific O

  2. Slide 2: Important Information

    Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

  3. Slide 3: Aerie Overview

    Aerie Overview Aerie IOP–Reducing Products (IP 2030+) ® ® • Rhopressa and Rocklatan commercialized in the United States • Glaucoma Franchise Approved in Europe • Globalization Plan Under Way Key Pipeline Activities • AR-15512 TRPM8 agonist for Dry Eye (advancing to Phase 3) • Retina Sustained-Releas

  4. Slide 4: U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs

    U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs 2020 U.S. Sales: $6.9B steroids, others, Beovu, $0.2 $0.1 $0.1 Intravitreal (IVT) Injection Lucentis, $1.5 Avastin, $0.04 Eylea, $4.9 • Frequent intravitreal injections required to maintain vision gains – Represents a signif

  5. Slide 5: Drug Delivery Platform: Bringing Small Molecule Chemistry to the Back of the Eye

    Drug Delivery Platform: Bringing Small Molecule Chemistry to the Back of the Eye Formulation and PRINT® Small Molecule Drug Manufacturing Candidates • DSM PEA Polymer • PLGA • Aerie Kinase Library (>4000 molecules) • PRINT® Mfg • Non-Aerie drug candidates • Bio-erodible, sustained-release implant fo

  6. Slide 6: AR-1105 (Dexamethasone) Implant Provides Validation of Aerie's Drug Delivery Platform

    AR-1105 (Dexamethasone) Implant Provides Validation of Aerie’s Drug Delivery Platform ® • AR-1105 implant manufactured via PRINT technology • Designed to provide at least 6 months of efficacy at a lower dose of dexamethasone than currently available therapies • Target indications: DME and RVO Implan

  7. Slide 7: AR-1105 Opportunity

    AR-1105 Opportunity • The DME market is growing in the United States and abroad – currently over $100M in the U.S. and nearly $300M in Europe • Potential benefits of the 6-month sustained efficacy of AR-1105, if approved: – Highly competitive dosing frequency for both the U.S. and European steroid m

  8. Slide 8: AR-13503 Implant: A First-in-Class ROCK/PKC Inhibitor For Retinal Disease

    AR-13503 Implant: A First-in-Class ROCK/PKC Inhibitor For Retinal Disease AR-13503 Implants Mouse OIR Model in Rabbit Eye Esterases Netarsudil AR-13503 ROCK2 Ki = 1 nM ROCK2 Ki = 0.2 nM • AR-13503 is active metabolite of netarsudil • New MOA has potential to improve outcomes by targeting vascular de

  9. Slide 9: AR-13503 Implant: Phase 1 Clinical Study Initiated, Advanced to Stage 2

    AR-13503 Implant: 6-month Phase 1 Clinical Study Initiated, Successfully Advanced to Stage 2 Stage 1: Safety in wAMD and DME Stage 2: Safety in DME https://clinicaltrials.gov/ct2/show/NCT03835884?term=AR-13503&draw=2&rank=1. AR-13503 is an investigational drug not yet approved by any regulatory auth

  10. Slide 10: AR-14034 SR (Axitinib): Small Molecule Anti-VEGF Opportunity

    AR-14034 SR (Axitinib): Small Molecule Anti-VEGF Opportunity Ranibizumab Bevacizumab 1 Aflibercept Brolucizumab • 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 2025 • Current anti-VEGF pipeline dominated by longer duration products targeting injection every 4 - 6 months • AR-14034 (axitinib

  11. Slide 11: AR-14034 SR (Axitinib): Preclinical Results Support Up to 12 Months Duration

    AR-14034 SR (Axitinib): Preclinical Results Support Up to 12 Months Duration in Clinic Cumulative Cumulative Drug Release In Vitro Release Rate in 1X PBS w/0.5% TWEEN 20 100 In vitro: In vivo Comparison 80 Percent drug released Time 60 In vitro In rabbits Day 14/16 10% 6-9% 40 Day 29/31 17% 14% 20 M

  12. Slide 12: Addressing Unmet Needs in Wet AMD & DME

    Addressing Unmet Needs in Wet AMD & DME Reduced Injection New Mechanism of Drug/Target Frequency Action AR-1105 Implant ✓ (Dexamethasone) AR-13503 Implant ✓✓ (ROCK/PKC Inhibitor) AR-14034 Implant (Axitinib Pan-VEGF ✓ (VEGF A/B)✓ (VEGF C/D) Inhibitor) AR-1105, AR-13503 and AR-14034 are development st

  13. Slide 13: Thank You

    THANK YOUTHANK YOU

Aerie Pharmaceuticals — OIS ASRS 2021 on 6ix